MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
J E Kim, K K Kim, Sun Young Kim, Joonsung Lee, S H Park, J O Park, Y S Park, Ho Yeong Lim, Won Ki Kang, S. T. Kim · Journal of Cancer · 2017
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2017
Abstract
Our results suggest that combination treatment with BRAF and MEK inhibitors might be a novel treatment strategy for MAP2K1 K57T-mutant CRC. This finding will be helpful to guide treatment of patients with CRC that is resistant to EGFR inhibitors.
Open the resolved locator · 10.7150/jca.19582
Metadata licence: OpenAlex metadata (CC0)